- Home
- NEUP vs APRE Comparison
NEUP vs APRE Comparison
Compare NEUP & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEUP
- APRE
- Stock Information
- Founded
- NEUP 1996
- APRE 2006
- Country
- NEUP United States
- APRE United States
- Employees
- NEUP N/A
- APRE N/A
- Industry
- NEUP
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEUP
- APRE Health Care
- Exchange
- NEUP Nasdaq
- APRE Nasdaq
- Market Cap
- NEUP 9.3M
- APRE 9.7M
- IPO Year
- NEUP N/A
- APRE 2019
- Fundamental
- Price
- NEUP $4.74
- APRE $1.80
- Analyst Decision
- NEUP Strong Buy
- APRE Strong Buy
- Analyst Count
- NEUP 1
- APRE 2
- Target Price
- NEUP $21.00
- APRE $15.50
- AVG Volume (30 Days)
- NEUP 10.9K
- APRE 21.4K
- Earning Date
- NEUP 05-23-2025
- APRE 05-14-2025
- Dividend Yield
- NEUP N/A
- APRE N/A
- EPS Growth
- NEUP N/A
- APRE N/A
- EPS
- NEUP N/A
- APRE N/A
- Revenue
- NEUP $662,715.00
- APRE $1,284,475.00
- Revenue This Year
- NEUP N/A
- APRE N/A
- Revenue Next Year
- NEUP N/A
- APRE N/A
- P/E Ratio
- NEUP N/A
- APRE N/A
- Revenue Growth
- NEUP N/A
- APRE 33.27
- 52 Week Low
- NEUP $2.12
- APRE $1.41
- 52 Week High
- NEUP $15.24
- APRE $5.90
- Technical
- Relative Strength Index (RSI)
- NEUP N/A
- APRE 53.94
- Support Level
- NEUP N/A
- APRE $1.45
- Resistance Level
- NEUP N/A
- APRE $1.70
- Average True Range (ATR)
- NEUP 0.00
- APRE 0.17
- MACD
- NEUP 0.00
- APRE 0.02
- Stochastic Oscillator
- NEUP 0.00
- APRE 64.34
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.